An Expanded Access Protocol for Patients Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
Latest Information Update: 21 Mar 2024
Price :
$35 *
At a glance
- Drugs Cerdulatinib (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Expanded access; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 18 Mar 2024 Status changed from recruiting to completed.
- 18 Feb 2021 New trial record